Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.

Yoshida M, Shimazu T, Matsuyama A.

Prog Cell Cycle Res. 2003;5:269-78. Review.

PMID:
14593721
2.

From discovery to the coming generation of histone deacetylase inhibitors.

Yoshida M, Matsuyama A, Komatsu Y, Nishino N.

Curr Med Chem. 2003 Nov;10(22):2351-8. Review.

PMID:
14529478
3.

HDAC inhibitors for the treatment of cancer.

Secrist JP, Zhou X, Richon VM.

Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Review.

PMID:
14763127
4.

The role of histone deacetylases (HDACs) in human cancer.

Ropero S, Esteller M.

Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Review.

5.
6.

Acetylation of proteins as novel target for antitumor therapy: review article.

Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A.

Amino Acids. 2004 Jul;26(4):435-41. Epub 2004 Jun 11. Review.

PMID:
15290351
7.

Anticancer activities of histone deacetylase inhibitors.

Bolden JE, Peart MJ, Johnstone RW.

Nat Rev Drug Discov. 2006 Sep;5(9):769-84. Review.

PMID:
16955068
8.

The structure and function of histone deacetylases: the target for anti-cancer therapy.

Zhang Y, Fang H, Jiao J, Xu W.

Curr Med Chem. 2008;15(27):2840-9. Review.

PMID:
18991639
9.

Histone deacetylase inhibitors.

Marks PA, Richon VM, Miller T, Kelly WK.

Adv Cancer Res. 2004;91:137-68. Review.

PMID:
15327890
10.

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

Expert Opin Investig Drugs. 2007 May;16(5):569-71. Review.

PMID:
17461732
11.

Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE.

Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. Review.

PMID:
17896917
12.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, M√ľnster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
13.

Histone acetylation and the cell-cycle in cancer.

Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG.

Front Biosci. 2001 Apr 1;6:D610-29. Review.

PMID:
11282573
14.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
15.

Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?

Chen JS, Faller DV, Spanjaard RA.

Curr Cancer Drug Targets. 2003 Jun;3(3):219-36. Review.

PMID:
12769690
16.

Histone deacetylases: target enzymes for cancer therapy.

Mottet D, Castronovo V.

Clin Exp Metastasis. 2008;25(2):183-9. Epub 2007 Dec 5. Review.

PMID:
18058245
17.

Histone deacetylation in epigenetics: an attractive target for anticancer therapy.

Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R.

Med Res Rev. 2005 May;25(3):261-309. Review.

PMID:
15717297
18.

Prospects: histone deacetylase inhibitors.

Dokmanovic M, Marks PA.

J Cell Biochem. 2005 Oct 1;96(2):293-304. Review.

PMID:
16088937
19.

Histone deacetylase inhibitors: latest developments, trends and prospects.

Moradei O, Maroun CR, Paquin I, Vaisburg A.

Curr Med Chem Anticancer Agents. 2005 Sep;5(5):529-60. Review.

PMID:
16178777
20.

Role of histone deacetylase inhibitors in the treatment of cancer (Review).

Mei S, Ho AD, Mahlknecht U.

Int J Oncol. 2004 Dec;25(6):1509-19. Review.

PMID:
15547685

Supplemental Content

Support Center